TTC3

Across TCGA pan-cancer cohorts, TTC3 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of TTC3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where TTC3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TTC3 is over-expressed in tumor, although a few such as KICH and KIRC show the opposite, repressed pattern.

LUAD, LIHC, and CHOL are the cancer types where TTC3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TTC3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	+0.704	<.001	7	view →
LIHC	Female	II,III,IV	+1.201	<.001	6	view →
CHOL	Male	All	+1.843	<.001	4	view →
KICH	All	All	−0.669	.001	4	view →
KIRC	Male	III,IV	−0.397	.007	4	view →
LUSC	Female	All	+0.538	.011	3	view →
PRAD	All	All	+0.241	.031	2	view →
KIRP	Male	All	−0.376	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

TTC3–LUAD

Open the LUAD breakdown →